DrugPatentWatch Database Preview

Details for Patent: 6,352,717

« Back to Dashboard

Which drugs does patent 6,352,717 protect, and when does it expire?

Patent 6,352,717 protects FORTOVASE and is included in one NDA.

Protection for FORTOVASE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty patent family members in thirty-four countries.

Summary for Patent: 6,352,717

Title:	Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses
Abstract:	The present invention provides a process for encapsulating a shear sensitive fill mass which contains a pharmaceutical active agent or nutrient, characterized in that said fill mass is heated and subsequently cooled, prior to the encapsulation. The invention also provides capsules comprising shear sensitive fill material obtained by the said process which have a high and constant dissolution rate.
Inventor(s):	Alex; Rainer (Weil am Rhein, DE), Gerhards; Jurgen (Arlesheim, CH), Kraemer-Pittrof; Ingeborg (Rheinfelden, DE), Oeschger; Richard (Rheinsulz, CH), Rades; Thomas (Dunedin, NZ)
Assignee:	Hoffman-La Roche Inc. (Nutley, NJ)
Application Number:	09/440,731
Patent Claim Types: see list of patent claims	Dosage form; Process; Formulation;

Drugs Protected by US Patent 6,352,717

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Hoffmann La Roche	FORTOVASE	saquinavir	CAPSULE;ORAL	020828-001	Nov 7, 1997		DISCN	Yes	No					Y

Foreign Priority and PCT Information for Patent: 6,352,717

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	98121831	Nov 17, 1998

International Family Members for US Patent 6,352,717

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	020013
Austria	274895
Australia	1775100